Comparative Pharmacology
Head-to-head clinical analysis: JUNIOR STRENGTH ADVIL versus JUNIOR STRENGTH MOTRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JUNIOR STRENGTH ADVIL versus JUNIOR STRENGTH MOTRIN.
JUNIOR STRENGTH ADVIL vs JUNIOR STRENGTH MOTRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibition, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
Cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day for OTC use.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription.
None Documented
None Documented
2-4 hours (terminal); prolonged in hepatic impairment and elderly.
1.5-2 hours in children; prolonged in neonates (up to 30 hours) and renal impairment. Clinical: short half-life requires frequent dosing for sustained antipyresis/analgesia.
Primarily renal (90% as glucuronide conjugates and 10% unchanged); <5% biliary/fecal.
Renal excretion of inactive metabolites and conjugates (>90%); less than 10% excreted unchanged. Fecal elimination minor (<5%).
Category C
Category C
NSAID Analgesic
NSAID Analgesic